Semper Paratus Acquisition (TVGN) Stock Price, News & Analysis

Company Overview

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Key Stats

• Today's Range: $0.83 to $0.91
• 50-Day Range: $0.87 to $1.43
• 52-Week Range: $0.26 to $3.09
• Volume: 918,240 shs
• Average Volume: 1.45 million shs
• Market Capitalization: $165.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Semper Paratus Acquisition Stock Analysis - MarketRank™

Semper Paratus Acquisition scored higher than 73% of companies evaluated by MarketBeat, and ranked 258th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Semper Paratus Acquisition has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Semper Paratus Acquisition has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.57% of the float of Semper Paratus Acquisition has been sold short.

Short Interest Ratio / Days to Cover

Semper Paratus Acquisition has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Semper Paratus Acquisition has recently increased by 3,719.30%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Semper Paratus Acquisition does not currently pay a dividend.

Dividend Growth

Semper Paratus Acquisition does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.57% of the float of Semper Paratus Acquisition has been sold short.

Short Interest Ratio / Days to Cover

Semper Paratus Acquisition has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Semper Paratus Acquisition has recently increased by 3,719.30%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.13

News Sentiment

Semper Paratus Acquisition has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Semper Paratus Acquisition this week, compared to 4 articles on an average week.

Search Interest

6 people have searched for TVGN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Semper Paratus Acquisition insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,768,993.00 in company stock.

Percentage Held by Insiders

73.24% of the stock of Semper Paratus Acquisition is held by insiders. A high percentage of insider ownership can be a sign of company health.

TVGN Stock Analysis - Frequently Asked Questions

How have TVGN shares performed this year?

Semper Paratus Acquisition's stock was trading at $1.03 at the beginning of 2025. Since then, TVGN stock has decreased by 12.6% and is now trading at $0.9005.

How do I buy shares of Semper Paratus Acquisition?

Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Semper Paratus Acquisition own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Semper Paratus Acquisition investors own include NVIDIA (NVDA), Candel Therapeutics (CADL), CXApp (CXAI), GlycoMimetics (GLYC), Rigetti Computing (RGTI), XTI Aerospace (XTIA) and Aldeyra Therapeutics (ALDX).

Company Calendar

• Today: 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TVGN
• Previous Symbol: NASDAQ:TVGN
• CIK: 1860871
• Web: www.semperparatusspac.com
• Phone: 913-579-4170
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Semper Paratus Acquisition: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +1,010.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.73 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -934.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.35
• Quick Ratio: 0.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.09) per share
• Price / Book: -10.01

Miscellaneous

• Outstanding Shares: 183,890,000
• Free Float: 49,210,000
• Market Cap: $165.59 million
• Optionable: N/A
• Beta: -0.77